What do we miss? ASAS non-responders on anti-TNF therapy show improvement in performance-based physical function

Salima F.E. Van Weely, J. Christiaan Van Denderen, Martijn P.M. Steultjens, Michael T. Nurmohamed, Ben A.C. Dijkmans, Joost Dekker, Irene E. Van der Horst-Bruinsma

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objective: A prospective study was conducted in order to establish whether AS patients, who are defined as non-responders after 3 months of anti-TNF therapy, show improvement on performance-based tests of physical functioning. Methods: At baseline and 3 months after the start of anti-TNF therapy, AS patients completed seven performance-based tests of physical functioning, questionnaires on self-reported physical functioning (BASFI) and disease activity (BASDAI), and a pain and a global patient assessment. The concordance between ≥20% intra-individual improvement on the performance-based test of physical functioning and (i) response to anti-TNF therapy [Assessment of SpondyloArthritis International Society 20% (ASAS20) response] and (ii) ≥20% intra-individual improvement on self-reported physical functioning (BASFI) was assessed. Results: One hundred AS patients were included, of which 82 patients completed all tests at both time points. After 3 months of anti-TNF therapy, 27 (32.9%) patients were categorized as non-responders according to the ASAS20 response criteria. Improvement in performance-based physical functioning was seen in 13 of the 27 non-responders (48.1%) (i.e. n = 13/82 = 15.9% of the total group). Furthermore, 30 (36.6%) patients showed no improvement on self-reported physical functioning (BASFI). However, 17 of the 30 (56.7%) patients did improve on the performance-based tests of physical functioning (i.e. n = 17/82 = 20.7% of the total group).Conclusion: After 3 months of anti-TNF therapy, performance-based tests of physical functioning showed improvement in 48.1% of the ASAS20 non-responders. With these performance-based tests, new information on outcome after anti-TNF therapy can be generated. Using performance-based tests alongside the BASFI could have additional value in the evaluation of outcomes for patients receiving anti-TNF therapy.

Original languageEnglish
Article numberket240
Pages (from-to)1884-1889
Number of pages6
JournalRheumatology
Volume52
Issue number10
DOIs
Publication statusPublished - 1 Jan 2013

Cite this

@article{77a8afe237cc4a86b1674fce36672f0e,
title = "What do we miss? ASAS non-responders on anti-TNF therapy show improvement in performance-based physical function",
abstract = "Objective: A prospective study was conducted in order to establish whether AS patients, who are defined as non-responders after 3 months of anti-TNF therapy, show improvement on performance-based tests of physical functioning. Methods: At baseline and 3 months after the start of anti-TNF therapy, AS patients completed seven performance-based tests of physical functioning, questionnaires on self-reported physical functioning (BASFI) and disease activity (BASDAI), and a pain and a global patient assessment. The concordance between ≥20{\%} intra-individual improvement on the performance-based test of physical functioning and (i) response to anti-TNF therapy [Assessment of SpondyloArthritis International Society 20{\%} (ASAS20) response] and (ii) ≥20{\%} intra-individual improvement on self-reported physical functioning (BASFI) was assessed. Results: One hundred AS patients were included, of which 82 patients completed all tests at both time points. After 3 months of anti-TNF therapy, 27 (32.9{\%}) patients were categorized as non-responders according to the ASAS20 response criteria. Improvement in performance-based physical functioning was seen in 13 of the 27 non-responders (48.1{\%}) (i.e. n = 13/82 = 15.9{\%} of the total group). Furthermore, 30 (36.6{\%}) patients showed no improvement on self-reported physical functioning (BASFI). However, 17 of the 30 (56.7{\%}) patients did improve on the performance-based tests of physical functioning (i.e. n = 17/82 = 20.7{\%} of the total group).Conclusion: After 3 months of anti-TNF therapy, performance-based tests of physical functioning showed improvement in 48.1{\%} of the ASAS20 non-responders. With these performance-based tests, new information on outcome after anti-TNF therapy can be generated. Using performance-based tests alongside the BASFI could have additional value in the evaluation of outcomes for patients receiving anti-TNF therapy.",
keywords = "Ankylosing spondylitis, Outcome assessment, Performance-based tests, Physical functioning",
author = "{Van Weely}, {Salima F.E.} and {Van Denderen}, {J. Christiaan} and Steultjens, {Martijn P.M.} and Nurmohamed, {Michael T.} and Dijkmans, {Ben A.C.} and Joost Dekker and {Van der Horst-Bruinsma}, {Irene E.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1093/rheumatology/ket240",
language = "English",
volume = "52",
pages = "1884--1889",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "10",

}

What do we miss? ASAS non-responders on anti-TNF therapy show improvement in performance-based physical function. / Van Weely, Salima F.E.; Van Denderen, J. Christiaan; Steultjens, Martijn P.M.; Nurmohamed, Michael T.; Dijkmans, Ben A.C.; Dekker, Joost; Van der Horst-Bruinsma, Irene E.

In: Rheumatology, Vol. 52, No. 10, ket240, 01.01.2013, p. 1884-1889.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - What do we miss? ASAS non-responders on anti-TNF therapy show improvement in performance-based physical function

AU - Van Weely, Salima F.E.

AU - Van Denderen, J. Christiaan

AU - Steultjens, Martijn P.M.

AU - Nurmohamed, Michael T.

AU - Dijkmans, Ben A.C.

AU - Dekker, Joost

AU - Van der Horst-Bruinsma, Irene E.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Objective: A prospective study was conducted in order to establish whether AS patients, who are defined as non-responders after 3 months of anti-TNF therapy, show improvement on performance-based tests of physical functioning. Methods: At baseline and 3 months after the start of anti-TNF therapy, AS patients completed seven performance-based tests of physical functioning, questionnaires on self-reported physical functioning (BASFI) and disease activity (BASDAI), and a pain and a global patient assessment. The concordance between ≥20% intra-individual improvement on the performance-based test of physical functioning and (i) response to anti-TNF therapy [Assessment of SpondyloArthritis International Society 20% (ASAS20) response] and (ii) ≥20% intra-individual improvement on self-reported physical functioning (BASFI) was assessed. Results: One hundred AS patients were included, of which 82 patients completed all tests at both time points. After 3 months of anti-TNF therapy, 27 (32.9%) patients were categorized as non-responders according to the ASAS20 response criteria. Improvement in performance-based physical functioning was seen in 13 of the 27 non-responders (48.1%) (i.e. n = 13/82 = 15.9% of the total group). Furthermore, 30 (36.6%) patients showed no improvement on self-reported physical functioning (BASFI). However, 17 of the 30 (56.7%) patients did improve on the performance-based tests of physical functioning (i.e. n = 17/82 = 20.7% of the total group).Conclusion: After 3 months of anti-TNF therapy, performance-based tests of physical functioning showed improvement in 48.1% of the ASAS20 non-responders. With these performance-based tests, new information on outcome after anti-TNF therapy can be generated. Using performance-based tests alongside the BASFI could have additional value in the evaluation of outcomes for patients receiving anti-TNF therapy.

AB - Objective: A prospective study was conducted in order to establish whether AS patients, who are defined as non-responders after 3 months of anti-TNF therapy, show improvement on performance-based tests of physical functioning. Methods: At baseline and 3 months after the start of anti-TNF therapy, AS patients completed seven performance-based tests of physical functioning, questionnaires on self-reported physical functioning (BASFI) and disease activity (BASDAI), and a pain and a global patient assessment. The concordance between ≥20% intra-individual improvement on the performance-based test of physical functioning and (i) response to anti-TNF therapy [Assessment of SpondyloArthritis International Society 20% (ASAS20) response] and (ii) ≥20% intra-individual improvement on self-reported physical functioning (BASFI) was assessed. Results: One hundred AS patients were included, of which 82 patients completed all tests at both time points. After 3 months of anti-TNF therapy, 27 (32.9%) patients were categorized as non-responders according to the ASAS20 response criteria. Improvement in performance-based physical functioning was seen in 13 of the 27 non-responders (48.1%) (i.e. n = 13/82 = 15.9% of the total group). Furthermore, 30 (36.6%) patients showed no improvement on self-reported physical functioning (BASFI). However, 17 of the 30 (56.7%) patients did improve on the performance-based tests of physical functioning (i.e. n = 17/82 = 20.7% of the total group).Conclusion: After 3 months of anti-TNF therapy, performance-based tests of physical functioning showed improvement in 48.1% of the ASAS20 non-responders. With these performance-based tests, new information on outcome after anti-TNF therapy can be generated. Using performance-based tests alongside the BASFI could have additional value in the evaluation of outcomes for patients receiving anti-TNF therapy.

KW - Ankylosing spondylitis

KW - Outcome assessment

KW - Performance-based tests

KW - Physical functioning

UR - http://www.scopus.com/inward/record.url?scp=84887388583&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/ket240

DO - 10.1093/rheumatology/ket240

M3 - Article

VL - 52

SP - 1884

EP - 1889

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 10

M1 - ket240

ER -